Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The Antiaging Protein Klotho Enhances Oligodendrocyte Maturation and Myelination of the CNS.
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain.
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
Sanofi MS drug nears green light after pass-the-parcel marathon
Differential roles of microglia and monocytes in the inflamed central nervous system.
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
Antiinflammatory effects of orientin-2″-o-galactopyranoside on lipopolysaccharide-stimulated microglia.
Integrated analysis of daclizumab HYP pharmacokinetics from three phase 1 studies
A genome-wide association study of brain lesion distribution in multiple sclerosis.
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica.
Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand.
Pharmacokinetic properties and metabolism of idebenone.
Genetics of multiple sclerosis: swimming in an ocean of data.
Estimating Time to Disease Progression Comparing Transition Models and Survival Methods-An Analysis of Multiple Sclerosis Data.
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.
Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis
Ofatumumab
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.

Pages